EORTC Quality of Life Group, Head and Neck Tumors, Brussels, Belgium; Radiation therapy Department, Brasília University, Brasília, DF, Brazil.
Radiation therapy Department, Brasília University, Brasília, DF, Brazil.
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):485-494. doi: 10.1016/j.ijrobp.2020.09.044. Epub 2020 Sep 29.
To compare global health-related quality of life (HRQoL) and overall survival (OS) in patients with head and neck cancer treated with intensity modulated radiation therapy (IMRT), conformal radiation therapy (3DCRT) or conventional radiation therapy (2DRT).
In this real-world, multi-institutional and prospective study, HRQoL outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Head and Neck 43 (H&N43) questionnaires. Item response theory was used to generate a global HRQoL score, based on the 71 questions from both forms. The effect of treatment modality on HRQoL was studied using multivariate regression analyses. Survival was estimated using the Kaplan-Meyer method, and groups were compared by the log-rank test.
Five hundred and seventy patients from 13 institutions were included. Median follow-up was 12.2 months. Concerning the radiation technique, 29.5% of the patients were treated with 2DRT, 43.7% received 3DCRT, and 26.8% were treated with IMRT. A higher proportion of patients receiving 2DRT had a treatment interruption of more than 5 days (69% vs 50.2% for 3DCRT and 42.5% for IMRT). IMRT had a statistically significant positive effect on HRQoL compared with 3DCRT (β= 2.627, standard error = 0.804, P = .001) and 2DRT had a statistically significant negative effect compared with 3DCRT (β= -5.075, standard error = 0.926, P < .001). Patients receiving 2DRT presented a worse OS (P = .01). There were no differences in OS when IMRT was compared with 3DCRT.
IMRT provided better HRQoL than 3DCRT, which provided better HRQoL than 2DRT. Patients receiving 2DRT presented a worse OS, which might be related to more frequent treatment interruptions.
比较头颈部癌患者接受调强放疗(IMRT)、适形放疗(3DCRT)或常规放疗(2DRT)后的全球健康相关生活质量(HRQoL)和总生存(OS)。
在这项真实世界、多机构和前瞻性研究中,使用欧洲癌症研究与治疗组织生活质量问卷核心 30 项(EORTC QLQ-C30)和欧洲癌症研究与治疗组织头颈部问卷 43 项(H&N43)评估 HRQoL 结果。基于两种形式的 71 个问题,采用项目反应理论生成一个全球 HRQoL 评分。使用多元回归分析研究治疗方式对 HRQoL 的影响。使用 Kaplan-Meier 法估计生存情况,并通过对数秩检验比较组间差异。
来自 13 个机构的 570 名患者被纳入研究。中位随访时间为 12.2 个月。关于放疗技术,29.5%的患者接受 2DRT,43.7%接受 3DCRT,26.8%接受 IMRT。接受 2DRT 的患者中断治疗超过 5 天的比例更高(69%比 3DCRT 的 50.2%和 IMRT 的 42.5%)。与 3DCRT 相比,IMRT 对 HRQoL 有统计学上的显著正向影响(β=2.627,标准误=0.804,P=0.001),而与 3DCRT 相比,2DRT 对 HRQoL 有统计学上的显著负向影响(β=-5.075,标准误=0.926,P<0.001)。接受 2DRT 的患者 OS 更差(P=0.01)。与 3DCRT 相比,IMRT 的 OS 无差异。
与 3DCRT 相比,IMRT 提供更好的 HRQoL,而 3DCRT 提供更好的 HRQoL 比 2DRT。接受 2DRT 的患者 OS 更差,这可能与更频繁的治疗中断有关。